Results 231 to 240 of about 23,181 (258)
Some of the next articles are maybe not open access.
Minor histocompatibility antigens: past, present, and future
Tissue Antigens, 2014AbstractMinor histocompatibility (H) antigens are key molecules driving allo‐immune responses in both graft‐versus‐host‐disease (GvHD) and in graft‐versus‐leukemia (GvL) reactivity in human leukocyte antigen (HLA)‐matched hematopoietic stem‐cell transplantation (HSCT).
Eric Spierings
exaly +3 more sources
Much ado about minor histocompatibility antigens
Immunology Today, 1998Abstract Current knowledge of histocompatibility (H) loci located outside of the major histocompatibility complex - i.e. those encoding the so-called minor H antigens - was surveyed at a recent meeting ∗ ∗The 1st International Symposium on Minor Histocompatibility Antigens was held at Bar Harbor, ME, USA, on 14–17 September 1997..
Simpson, E, Roopenian, D, Goulmy, E
openaire +3 more sources
Minor Histocompatibility Antigens
The Cancer Journal, 2004Minor histocompatibility antigens have to be considered as key molecules in the stem cell-based immunotherapy of malignancies. Allogeneic stem cell transplantation (SCT) is a well-established and effective therapy for advanced hematologic malignancies.
openaire +2 more sources
Molecular Typing Methods for Minor Histocompatibility Antigens
2013Minor histocompatibility (H) antigen mismatching leads to clinically relevant alloimmune reactivity. Depending on the tissue expression pattern of the involved minor H antigens, the immune response may either cause graft-versus-host disease and a graft-versus-tumor effect or lead to only a graft-versus-leukemia effect. Thus, identification of recipient-
openaire +2 more sources
IMMUNE RESPONSE TO MINOR HISTOCOMPATIBILITY ANTIGENS
Transplantation, 1972L W, Schierman, R A, McBride
openaire +2 more sources
Risk assessment in haematopoietic stem cell transplantation: Minor histocompatibility antigens
Best Practice and Research in Clinical Haematology, 2007Lothar Hambach +2 more
exaly